LunGuard has created a unique, patent protected, enteral feeding and airway management device which is compatible with most feeding pumps and ventilation devices. By safely reducing reflux, measuring the esophageal pressure and securing the endotracheal tube seal, LunGuard creates an integrated solution to manage and mitigate recognized and costly risks associated with supporting critically ill patient's breathing and feeding, including Ventilator Associated Pneumonia (VAP).
Forty percent (40%) of critical care patients are mechanically ventilated, sedated and fed through nasogastric (NG) tubes1. As a result, there is an open channel from these patients' stomach into their lungs through which gastric reflux fluids with bacteria can travel and cause severe or deadly lung infections and complications. In fact, 90% of enterally-fed patients aspirate gastric contents2. Therefore, gastro esophageal reflux in mechanically ventilated patients, who are also enterally-fed, is recognized as a major contributing factor to the development of Ventilator Associated Pneumonia (VAP). Overall, VAP alone is estimated to add ~$3.1B, each year, to the healthcare costs in the USA. VAP complications lead, on average, to extra Length of Stay (LOS) at the ICU of 4-6 days, per patient; and increases mortality rates by 33%. Therefore, the caregivers and providers have a clear clinical and financial interest to prevent VAP and to reduce its cost.
(1) A smart disposable NG feeding tube with 3 distal balloons positioned in the lower third of the esophagus to reduce reflux and remove bacterially contaminated secretions from the esophagus 24/7, thereby protecting the patient from VAP and increasing patient comfort and satisfaction. Reduction of gastric reflux also enables caregivers to avoid reducing and/or delaying feeding protocols as early nutritional support improves wound healing and shortens the LOS; (2) Continuous monitoring of the esophageal pressure for an accurate measurement of the trans-pulmonary pressure, without needing a separate catheter, enables weaning the patient from mechanical ventilation 1.68 days earlier; (3) A pneumatic controller for the endotracheal tube cuff, protecting the trachea from oral secretions and providing a second barrier for gastric bacteria.
Product: LunGuard has successfully completed several clinical and pre-clinical studies proving the safety and efficacy of the device. Recently, LunGuard completed a clinical study in critically ill patients which clearly demonstrated the significant benefits and efficacy of the system.
IP: LunGuard's key patent has been granted in several territories, including the USA and China; additional patents are in PCT phase.
The global market for feeding devices by feeding tubes, was worth over $1.64Bn in 2011, and is expected to reach $2.5Bn in 2018. The global market for mechanical ventilators was worth $1.1Bn in 2015 and is expected to reach $1.8Bn by 2024. The global market for safety enhanced medical devices for infection prevention (including specialty catheters and tubes) is estimated to be ~$5.6Bn in 2016 and is expected to grow to $8Bn by 2023.